ICUCW · Insider Trading
SeaStar Medical Holding Corporation Warrant
Every open-market purchase and sale reported by ICUCW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-10 | Bradford K Towne | Principal Accounting Officer | A | +7,500 | — |
| 2026-02-10 | John Neuman | Director | A | +3,000 | — |
| 2026-02-10 | Kevin Chung | Chief Medical Officer | A | +15,000 | — |
| 2026-02-10 | Bernadette N Vincent | Director | A | +3,000 | — |
| 2026-02-10 | Eric Schlorff | Chief Executive Officer | A | +30,000 | — |
| 2026-02-10 | Kenneth Van Heel | Director | A | +3,000 | — |
| 2026-02-10 | Jennifer A Baird | Director | A | +3,000 | — |
| 2025-12-22 | Jennifer A Baird | Director | Buy | +4,200 | +$987 |
| 2025-12-11 | Michael Messinger | Chief Financial Officer | Buy | +14,500 | +$5.10K |
| 2025-08-28 | Kenneth Van Heel | Director | Buy | +35,000 | +$30.81K |
| 2025-08-25 | Kevin Chung | Chief Medical Officer | Buy | +10,000 | +$8.00K |
| 2025-07-16 | Bernadette N Vincent | Director | MIXED | +6,667 | — |
| 2025-07-16 | John Neuman | Director | MIXED | +6,667 | — |
| 2025-07-16 | Kenneth Van Heel | Director | MIXED | +8,000 | — |
| 2025-07-16 | Jennifer A Baird | Director | A | +4,000 | — |
| 2025-07-03 | Kevin Chung | Chief Medical Officer | M | +5,000 | — |
| 2025-07-03 | Eric Schlorff | Chief Executive Officer | M | +21,667 | — |
| 2025-07-02 | Jennifer A Baird | Director | MIXED | +12,667 | +$4.17K |
| 2025-06-27 | John Neuman | Director | Buy | +40,000 | +$14.40K |
| 2025-05-22 | Jennifer A Baird | Director | Buy | +10,000 | +$12.81K |
| 2025-05-20 | Kevin Chung | Chief Medical Officer | Buy | +4,500 | +$5.62K |
| 2025-04-03 | Kevin Chung | Chief Medical Officer | A | +15,000 deriv. | — |
| 2025-04-03 | David A Green | Chief Financial Officer | A | +15,000 deriv. | — |
| 2025-02-27 | John Neuman | Director | Buy | +40,000 | +$153.23K |
| 2024-12-03 | Bernadette N Vincent | Director | A | +8,000 deriv. | — |
| 2024-12-03 | Jennifer A Baird | Director | A | +8,000 deriv. | — |
| 2024-11-19 | Kevin Chung | Chief Medical Officer | Buy | +4,250 | +$8.46K |
| 2024-11-19 | Eric Schlorff | Chief Executive Officer | A | +65,000 deriv. | — |
| 2024-11-15 | Kenneth Van Heel | Director | A | +4,000 deriv. | — |
| 2024-11-15 | Rick Barnett | Director | A | +4,000 deriv. | — |
| 2024-11-15 | Allan Collins | Director | A | +4,000 deriv. | — |
| 2024-11-15 | John Neuman | Director | A | +8,000 deriv. | — |
| 2024-10-01 | Kevin Chung | Chief Medical Officer | Buy | +1,000 | +$4.26K |
| 2024-09-09 | David A Green | Chief Financial Officer | A | +18,000 deriv. | — |
| 2024-09-09 | David A Green | Chief Financial Officer | A | +10,323 | — |
| 2024-04-16 | Allan Collins | Director | A | +37,943 | — |
| 2024-04-16 | Bruce M. Rodgers | Director | A | +36,537 | — |
| 2024-04-16 | Richard D. Russell | Director | A | +32,322 | — |
| 2024-04-16 | Kenneth Van Heel | Director | A | +43,564 | — |
| 2024-04-16 | Andres Lobo | Director | A | +32,322 | — |
| 2024-04-16 | David A Green | Chief Financial Officer | A | +752,500 | — |
| 2024-04-16 | Rick Barnett | Director | A | +70,264 | — |
| 2023-11-29 | Kevin Chung | Chief Medical Officer | A | +63,422 | — |
| 2023-11-29 | Eric Schlorff | Chief Executive Officer | A | +60,248 | — |
| 2023-11-29 | Caryl Baron | Interim CFO | MIXED | +35,363 | — |
| 2023-11-28 | Eric Schlorff | Chief Executive Officer | A | +33,750 | — |
| 2023-11-28 | Kevin Chung | Chief Medical Officer | A | +28,125 | — |
| 2023-11-28 | Eric Schlorff | Chief Executive Officer | A | +20,317 | — |
| 2023-11-27 | Kenneth Van Heel | Director | Buy | +100,000 | +$40.00K |
| 2023-09-19 | Caryl Baron | Interim CFO | A | +4,110 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Rick Barnett | Director | 86,664 | $702 |
| Allan Collins | Director | 54,343 | $440 |
| Eric Schlorff | Chief Executive Officer | 39,852 | $323 |
| Kevin Chung | Chief Medical Officer | 20,819 | $169 |
| Michael Messinger | Chief Financial Officer | 17,500 | $142 |
| John Neuman | Director | 12,200 | $99 |
| Bradford K Towne | Principal Accounting Officer | 9,050 | $73 |
| Kenneth Van Heel | Director | 7,940 | $64 |
| Jennifer A Baird | Director | 6,620 | $54 |
| Bernadette N Vincent | Director | 4,200 | $34 |
| David A Green | Chief Financial Officer | 2,223 | $18 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ICUCW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.